Action NRIX NURIX THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Nurix Therapeutics, Inc.

Actions

NRIX

US67080M1036

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 08/05/2024 		Varia. 5j. Varia. 1 janv.
13,98 USD -1,27 % Graphique intraday de Nurix Therapeutics, Inc. +6,88 % +35,47 %
12/04 Le secteur des soins de santé est stable avant la cloche vendredi MT
12/04 Mise à jour sectorielle : Soins de santé MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Sector Update: Health Care
North American Morning Briefing : Big Banks Kick off Earnings Season
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours
Nurix Therapeutics Announces Proposed Public Offering
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M
North American Morning Briefing : Traders Await -2-
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NRIX
  4. Actualités Nurix Therapeutics, Inc.
  5. Autres langues